denosumab Archives - ACR Meeting Abstracts

Abstract Number: 1875 • ACR/ARP Annual Meeting 2019
Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
David Kendler¹, Arkadi Chines ², Patricia Clark ³, Peter R. Ebeling ⁴, Michael McClung ⁵, Yumie Rhee ⁶, Shuang Huang ², Robert Kees Stad ⁷ and Nick Freemantle ⁸, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico, ⁴Monash University, Melbourne, Victoria, Australia, ⁵Oregon Osteoporosis Center, Portland, OR, ⁶Yonsei University College of Medicine, Seoul, Republic of Korea, ⁷Amgen Inc., Rotkreuz, Zug, Switzerland, ⁸University College London, London, England, United Kingdom
Background/Purpose: There are limited data on patients transitioning from denosumab (DMAb) to bisphosphonates (BPs). The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531) reported that alendronate…
Abstract Number: 1876 • ACR/ARP Annual Meeting 2019
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Kenneth Saag¹, Michele McDermott ², Jonathan Adachi ³, Willem Lems ⁴, Nancy Lane ⁵, Piet Geusens ⁶, Peter Butler ², Li Chen ², Daria Crittenden ², Robin Dore ⁷ and Stanley Cohen ⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴VU University Medical Centre, Amsterdam, Netherlands, ⁵University of California at Davis Medical Center, Sacramento, CA, ⁶Maastricht University, Maastricht, Netherlands, ⁷Robin K Dore Inc, Tustin, CA, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Denosumab, a monoclonal antibody against RANKL, is approved for the treatment of glucocorticoid (GC) induced osteoporosis (GiOP). In postmenopausal women with osteoporosis, denosumab discontinuation…
Abstract Number: 2215 • ACR/ARP Annual Meeting 2019
Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab
David Dempster¹, Peter Butler ², Mathias Bostrom ³, Jeri Nieves ¹, Hua Zhou ⁴, Li Chen ², Nicola Pannacciulli ², Rachel Wagman ² and Felicia Cosman ¹, ¹Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Hospital for Special Surgery, New York, NY, ⁴Helen Hayes Hospital, West Haverstraw, NY
Background/Purpose: Denosumab (DMAb) is a potent antiresorptive agent, but findings in non-human primates suggest that modeling-based bone formation (MBBF) may persist despite DMAb treatment (Ominsky…
Abstract Number: 1818 • ACR/ARHP Annual Meeting 2018
Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Osvaldo D. Messina⁵, Jorge Morales-Torres⁶, Ronald Emkey⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aries, Argentina, ⁶Hospital Aranda de la Parra, Leon, Mexico, ⁷Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…
Abstract Number: 2299 • ACR/ARHP Annual Meeting 2018
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Eric Lespessailles⁵, Jorge Malouf⁶, Bente Langdahl⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Aarhus University, Aarhus, Denmark, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
Abstract Number: 2313 • ACR/ARHP Annual Meeting 2018
The Efficacy of Denosumab for Prevention of Osteoporotic Fractures in Patients with Connective Tissue Diseases Receiving Very High Doses of Glucocorticoid
Keiichiro Kadoba, Keisuke Nishimura, Hiroki Mukoyama, Rintaro Saito, Daisuke Waki and Toshihiko Yokota, Department of Endocrinoligy and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan
Background/Purpose: Osteoporosis is a common complication of glucocorticoid therapy, contributing to significant morbidity especially in patients receiving very high doses of glucocorticoid (GC). There have…
Abstract Number: 2809 • ACR/ARHP Annual Meeting 2018
Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
Serge Ferrari¹, E. Michael Lewiecki², Peter W. Butler³, David L Kendler⁴, Nicola Napoli⁵, Shuang Huang³, Daria B Crittenden³, Nicola Pannacciulli³, E.S. Siris⁶ and Neil Binkley⁷, ¹Geneva University Hospital, Geneva, Switzerland, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Amgen Inc., Thousand Oaks, CA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Columbia University Medical Center, New York, NY, ⁷University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI
Background/Purpose: Osteoporosis is a chronic disease, yet skeletal safety events—atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ)—remain a concern with long-term treatment. Ten…
Abstract Number: 323 • ACR/ARHP Annual Meeting 2017
Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated for up to 10 Years with Denosumab: Results from a Phase 3 Open-Label Extension Study
Nelson B. Watts¹, John T. Grbic², Neil Binkley³, Peter W. Butler⁴, Xiang Yin⁴, Antoniette Tierney⁴, Rachel B. Wagman⁴ and Michael McClung⁵, ¹Mercy Health, Cincinnati, OH, ²Columbia University, New York, NY, ³University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Oregon Osteoporosis Center, Portland, OR
Background/Purpose: Antiresorptive therapy use is associated with osteonecrosis of the jaw (ONJ), an infrequent but serious adverse event. Positively adjudicated ONJ in the denosumab (DMAb)…
Abstract Number: 324 • ACR/ARHP Annual Meeting 2017
The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study
Kyosuke Hattori¹, Yuji Hirano¹, Yasuhide Kanayama², Nobunori Takahashi³, Naoki Ishiguro³ and Toshihisa Kojima³, ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Although early intensive treatment has improved medication of rheumatoid arthritis (RA), treatment for osteoporosis (OP) in RA patient will be more important. Here, we…
Abstract Number: 1435 • ACR/ARHP Annual Meeting 2017
Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies
Yoshiya Tanaka¹, Tsutomu Takeuchi², Satoshi Soen³, Naoki Ishiguro⁴, Hisashi Yamanaka⁵, Toshiyuki Yoneda⁶, Sakae Tanaka⁷, Takaya Nitta⁸, Naoki Okubo⁹, Harry K. Genant¹⁰ and Désirée van der Heijde¹¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Kindai University Nara Hospital, Ikoma, Japan, ⁴Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Indiana University School of Medicine, Indianapolis, IN, ⁷Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Japan, ⁸Daiichi Sankyo Co., Ltd., Tokyo, Japan, ⁹DaiichiSankyo CO., LTD., Tokyo, Japan, ¹⁰University of California, San Francisco, CA, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by blocking RANKL. Phase 2 (DRIVE) and phase 3 (DESIRABLE) studies…
Abstract Number: 1850 • ACR/ARHP Annual Meeting 2017
Efficacy of Zoledronic Acid and Denosumab in the Treatment of Patients with Low Back Pain and Modic Changes: A Proof of Principle Trial
Guoqi Cai¹, Laura Laslett¹, Dawn Aitken², Andrew Halliday³, Feng Pan², Petr Otahal¹, Deb Speden⁴, Tania Winzenberg¹ and Graeme Jones², ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Radiology, Royal Hobart Hospital, Hobart, Australia, ⁴Royal Hobart Hospital, Hobart, Australia
Background/Purpose: Low back pain (LBP) is a common and debilitating problem. There are currently very limited pharmacological treatments for LBP. Vertebral endplate subchondral bone abnormalities…
Abstract Number: 1886 • ACR/ARHP Annual Meeting 2017
Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
E Michael Lewiecki¹, Rajani V Dinavahi², Marise Lazaretti-Castro³, Peter R Ebeling⁴, J Adachi⁵, Akimitsu Miyauchi⁶, Evelien Gielen⁷, Cassandra E Milmont², Cesar Libanati⁸ and Andreas Grauer², ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of São Paulo, São Paulo, Brazil, ⁴Monash University, Melbourne, Australia, ⁵McMaster University, Hamilton, ON, Canada, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷University Hospitals Leuven, Leuven, Belgium, ⁸UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis…
Abstract Number: 1887 • ACR/ARHP Annual Meeting 2017
Ten-Year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis with Denosumab Treatment
S Ferrari¹, PW Butler², DL Kendler³, Paul D Miller⁴, C Roux⁵, AT Wang², Rachel B. Wagman² and EM Lewiecki⁶, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵Paris Descartes University, Paris, France, ⁶New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Background/Purpose: Treatment with denosumab (DMAb) for 3 years significantly reduces the incidence of nonvertebral fractures (NVFx; Cummings NEJM 2009). While there are limited data describing…
Abstract Number: 1888 • ACR/ARHP Annual Meeting 2017
Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 12 Months in Subgroups of Glucocorticoid-Treated Individuals
Kenneth Saag¹, N Pannacciulli², P Geusens³, J Adachi⁴, Eric Lespessailles⁵, J Malouf⁶, O Messina⁷, AT Wang², Rachel B. Wagman² and WF Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Cosme Argerich Hospital, Buenos Aries, Argentina, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. We previously demonstrated that denosumab (DMAb) significantly increased lumbar spine (LS) BMD…
Abstract Number: 1889 • ACR/ARHP Annual Meeting 2017
Safety and Efficacy of Denosumab Among Subjects with Mild-to-Moderate Chronic Kidney Disease (CKD) in the “Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months” Extension Study
Aaron Broadwell¹, Peter R Ebeling², Edward Franek³, Stefan Goemaere⁴, Rachel B. Wagman⁵, Xiang Yin⁵, Susan Yue⁵ and Paul D Miller⁶, ¹Rheumatology and Osteoporosis Specialists, Shreveport, LA, ²Monash University, Clayton, Australia, ³Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: As renal function may decline with age, it is important to understand the safety and efficacy of therapeutic agents for postmenopausal osteoporosis (PMO) and…

Abstracts tagged "denosumab"